What's with the Creso Pharma (ASX:CPH) share price today?

The Creso Pharma (ASX: CPH) share price has slipped this afternoon despite a "transformational" acquisition into the psychedelics market.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price has slipped in afternoon trading today after the company announced an agreement to acquire Halucenex Life Sciences Inc.

The Creso Pharma share price lifted as high as 23 cents just after the market opened this morning as the agreement provides entry into the emerging global market for psychedelic medicines, estimated to be worth up to US$100 billion. Halucenex researches, develops and licences novel psychedelic molecules for the global pharmaceutical and nutraceutical markets. 

However, Creso shares are currently down 1.43%, trading at 20.7 cents at the time of writing. Let's take a look at what's happening with the Creso Pharma share price. 

Consolidating after 1,000% surge last year 

The Creso Pharma share price surged as much as ~1,300% last year from 3.5 cents to as high as 47 cents.

This could be attributed to the US House of Representatives passing the Marijuana Opportunity Reinvestment and Expungement Act to remove cannabis from the US Controlled Substances Act. The bill decriminalises cannabis for the first time on a national level. 

While the Creso Pharma share price has taken a breather around the 20 cent level in 2021, the company continues to push forward with several significant announcements and developments in the cannabis space.  

Halucenex acquisition 

Creso said the acquisition was a "first-mover advantage" into the psychedelic medicines sector, positioning itself as the first 100%-owned psychedelic medicines company listed on the ASX. 

Halucenex is currently awaiting the approval of its Controlled Drugs and Substances Dealer's License. If approved, it will apply to commence a phase 2 clinical trial. The company will conduct research and development on psychedelic substances, including LSD, psilocybin and MDMA. Its phase 2 clinical trial is expected to commence in the third quarter of 2021. 

Halucenex will also seek an amendment to the dealer's license to produce, package/assemble, sell, transport, import and export psychedelic substances. The company notes that it will not partake in any activities in relation to certain compounds until the company has satisfied the ASX that it is legally compliant. 

Transformational acquisition for the Creso Pharma share price 

Creso Pharma views the acquisition as "transformational", enabling the company to emerge as a "best-in-class provider of cannabis, cannabinoids and psychedelics alternative medicines to meet the large unmet need for treatments to improve mental health and well being". 

The Halucenex acquisition will include a $500,000 cash consideration plus ~29.25 million Creso shares and ~17.5 million Creso performance shares. Creso has also agreed to advance Halucenex $250,000 as a loan to fund its operations before settlement. And provide another $1,000,000 in funding during the 12 months following settlement. 

Management commentary

Creso Pharma non-executive chairman Adam Blumenthal believes the acquisition benefits the company on all fronts.

This is a major milestone for Creso Pharma and marks our evolution into a broader based pharmaceutical business. Creso will now sell its trusted cannabis products and progress the commercialisation of a range of psychedelic-assisted psychotherapy treatments. Our entry into this market provides the company with another lucrative vertical and an additional near term revenue stream.

Mental health and PTSD are becoming detrimental to our society and this has been highlighted in the last 12 months. These conditions have been exacerbated by COVID-19 and the available treatments are shown to have limited effectiveness and many side effects. Psychedelic-assisted therapy is a new alternative treatment route, which has considerable promise.

Mr Blumenthal said the acquisition of Halucenex would strengthen the company's presence in Canada, as well as "provide a number of opportunities in drug development which will inevitably lead to further new market entries and commercialisation opportunities".

Should you invest $1,000 in Magellan Financial Group right now?

Before you buy Magellan Financial Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Magellan Financial Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

More on Share Market News

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

These ASX 200 stocks could rise 25% to 40% after the market selloff

Analysts believe these shares have the potential to generate big returns over the next 12 months.

Read more »

Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A male investor sits at his desk pondering at his laptop screen with a piece of paper in his hand.
Share Market News

Is the ASX 200 on the verge of a market correction?

Here's how close we are to a market correction after another horror week.

Read more »

a man with hands in pockets and a serious look on his face stares out of an office window onto a landscape of highrise office buildings in an urban landscape
REITs

Why this could be a great ASX share sector to invest in right now

This could be a smart play right now.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

How an $8k investment in this ASX All Ords stock one-year ago is worth $58,182 today

The ASX All Ords stock has enjoyed a stellar year. But why?

Read more »

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finally caught a break this Friday.

Read more »

A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
Share Market News

It's official: US stock market enters correction

The S&P 500 is now down 10.13% from its most recent peak.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »